1. Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud. 2. Investors are advised to contact the firm for a class action claim. 3. ADC's recent clinical trial data reported adverse events affecting stock price negatively. 4. On December 3, ADC's stock dropped 14.13% to close at $3.95 per share. 5. Cytokine release syndrome was observed in 36.7% of trial patients.
FAQ
Why Very Bearish?
The ongoing investigation may lead to further declines in investor confidence. Historical examples show similar allegations have often resulted in significant stock price drops.
How important is it?
The investigation's implications for potential fraud may significantly impact investor sentiment and stock price.
Why Short Term?
The immediate impact from the investigation and recent trial results are expected to affect ADCT's price swiftly. Past instances show that such developments typically influence stock performance within weeks.
Related Companies
Investor Alert: Pomerantz Law Firm Investigates ADC Therapeutics (ADCT) Claims
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP has initiated an investigation into claims on behalf of investors of ADC Therapeutics SA (NYSE: ADCT). The firm is assessing potential securities fraud or other unlawful business practices involving ADC and certain of its officers and/or directors. Investors are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for more information.
Background of the Investigation
The focus of Pomerantz's investigation comes after ADC Therapeutics released updated data from the LOTIS-7 Phase 1b open-label clinical trial on December 3, 2025. This trial evaluated the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Although the press release highlighted positive outcomes, it also indicated that adverse events occurred in two patients, with one deemed to be treatment-related. Notably, ADC reported that cytokine release syndrome of all grades was observed in 36.7% of patients across various dose levels.
Stock Impact Following Clinical Data Release
In reaction to the clinical data release, shares of ADC Therapeutics experienced a significant decline. On December 3, 2025, the stock price fell by $0.65 per share, equating to a 14.13% drop, closing at $3.95 per share.
Pomerantz LLP Overview
Pomerantz LLP, with offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is well-regarded in corporate, securities, and antitrust class litigation. Established by the late Abraham L. Pomerantz, recognized as the dean of the class action bar, the firm has a distinguished history of advocating for victims of securities fraud and corporate misconduct.
With over 85 years of experience, Pomerantz has successfully secured numerous multimillion-dollar damages awards on behalf of its clients. For further information, please visit www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information
For inquiries regarding this investigation, please contact:
- Name: Danielle Peyton
- Firm: Pomerantz LLP
- Email: dpeyton@pomlaw.com
- Phone: 646-581-9980, ext. 7980